In a recent piece for TheJournal of Healthcare Contracting, Healthcare Supply Chain Association (HSCA) President Curtis Rooney details the findings of a new survey of hospitals and academic medical centers on the impact of changes to the distribution channels for specialty cancer therapies from the biotechnology company Genentech. The survey, commissioned by HSCA member Novation, specifically found the following hospital perceptions about Genentech’s policy change:
Sixty-three percent of Genentech customers said that the current delivery scheme is less reliable than the previous one;
Ninety-three percent said that they had experienced no issues with the previous distribution model;
Eighty-eight percent now report a delay in patient treatment because at least one of the drugs was unavailable;
Eighty-one percent are confirming that the change is having a “moderate to significant impact” on their historic budgeted expenses.
Last fall, HSCA, the American Hospital Association (AHA) and other leading hospital advocacy groups and individual hospitals sent aletter to Genentech urging the company to continue delivering the cancer therapies through the traditional distribution channels “so that our hospitals can focus on providing the best care for their cancer patients.”
To read the full piece in The Journal of Healthcare Contracting,click here